Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Denosumab Prior Auth Policy Update | OpenPay…
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0331

    Denosumab Products (Prolia) Prior Authorization

    Customize your policy alerts

    Sign up for Cigna Policy IP0331 alerts

    Get alerted when Policy IP0331 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Prolia and specified denosumab biosimilars used to treat osteoporosis or cancer-treatment-related bone loss. It applies to health benefit plans administered by Cigna Companies, subject to the member’s benefit plan, applicable law, and any controlling coverage mandate.

    Policy Summary
    PayerCigna
    PolicyDenosumab Products (Prolia) Prior Authorization
    Policy CodePolicy IP0331
    Change TypeModified
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with the applicable diagnosis, clinical criteria, requested dose, and frequency.
    SourceLink
    POLICY UPDATE CHANGES

    Treatment of bone loss in patients with prostate cancer receiving androgen deprivation therapy was added as an approval condition with a 1-year approval period and dosing of 60 mg subcutaneously every 6 months.

    Increasing bone mineral density in patients with breast cancer was added as an approval condition with a 1-year approval period and dosing of 60 mg subcutaneously every 6 months.

    Additional denosumab biosimilars, including Enoby, Bosaya, Osvyrti, and products represented by the listed billing codes, were added with the same medical-necessity criteria as Prolia and other covered biosimilars.

    Preferred product criteria were removed from the coverage policy.

    Concurrent use with other denosumab products was added as a condition not recommended for approval.

    An exception was added allowing a postmenopausal osteoporosis patient with a very low T-score below -3.0 to bypass the bisphosphonate trial.

    Additional billing codes for denosumab products and biosimilars were added or updated.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    9Denosumab products listed
    60 mg every 6 monthsStandard dose
    1 yearStandard approval duration
    7Covered indication pathways
    Ospomyv excludedPlan-specific restriction
    8Billing codes listed

    Coverage Criteria

    FDA-approved breast cancer indication

    Covered when ALL of the following are met.

    Required conditions

    • Breast cancer status: Patient has breast cancer that is not metastatic to bone.
    • Adjuvant therapy: Patient is receiving adjuvant aromatase inhibitor therapy.

    FDA-approved prostate cancer indication

    Covered when ALL of the following are met.

    Required conditions

    • Cancer status: Patient has prostate cancer that is not metastatic to bone.
    • Androgen deprivation condition: Patient is receiving androgen deprivation therapy or has undergone bilateral orchiectomy.

      Examples of androgen deprivation therapy include Camcevi, Lupron Depot, Eligard, Firmagon, Orgovyx, Trelstar, and Zoladex.

    Glucocorticoid-induced osteoporosis

    Covered when ALL of the following are met.

    Required conditions

    • Systemic glucocorticoid use: Patient is initiating or continuing chronic systemic glucocorticoids.
    • Qualifying pathway: Patient has tried intravenous zoledronic acid; or has tried an oral bisphosphonate with inadequate efficacy after 12 months or significant intolerance; or cannot take an oral bisphosphonate because of swallowing difficulty, inability to remain upright, or a gastrointestinal condition; or has severe renal impairment or chronic kidney disease with CKD-MBD evaluation; or has had an osteoporotic or fragility fracture.Severe renal impairment example: creatinine clearance < 35 mL/minute; inadequate efficacy trial: 12 months.

      Examples of intolerance include severe gastrointestinal or musculoskeletal adverse events. Gastrointestinal conditions may include esophageal lesions, ulcers, stricture, or achalasia.

    Postmenopausal osteoporosis

    Covered when ALL of the following are met.

    Required conditions

    • Bone disease or fracture criterion

      • Low bone mass with high fracture risk: Patient has low bone mass and the prescriber documents high fracture risk.
    • Qualifying prior therapy or clinical-need criterion: Patient has tried intravenous ibandronate or zoledronic acid; or has tried an oral bisphosphonate with inadequate efficacy after 12 months or significant intolerance; or cannot take an oral bisphosphonate because of swallowing difficulty, inability to remain upright, or a gastrointestinal condition; or has severe renal impairment or chronic kidney disease with CKD-MBD evaluation; or has had an osteoporotic or fragility fracture; or has a very low T-score.Severe renal impairment example: creatinine clearance < 35 mL/minute; very low T-score: < -3.0.

    Osteoporosis treatment in men

    Covered when ALL of the following are met.

    Required conditions

    • Bone disease or fracture criterion

      • Low bone mass with high fracture risk: Patient has low bone mass and the prescriber documents high fracture risk.
    • Qualifying prior therapy or clinical-need criterion: Patient has tried intravenous zoledronic acid; or has tried an oral bisphosphonate with inadequate efficacy after 12 months or significant intolerance; or cannot take an oral bisphosphonate because of swallowing difficulty, inability to remain upright, or a gastrointestinal condition; or has severe renal impairment or chronic kidney disease with CKD-MBD evaluation; or has had an osteoporotic or fragility fracture.Severe renal impairment example: creatinine clearance < 35 mL/minute.

    Supportive-evidence prostate cancer pathway

    Covered when the stated criterion is met.

    Androgen deprivation therapy: Patient with prostate cancer is receiving androgen deprivation therapy for treatment of bone loss.Approve for 1 year; 60 mg subcutaneously once every 6 months.

    Examples include Camcevi, Lupron Depot, Eligard, Firmagon, Trelstar, Zoladex, and Orgovyx.

    Supportive-evidence breast cancer pathway

    Covered when ONE of the following pathways is met.

    Breast cancer pathway

    • Postmenopausal pathway: Patient is postmenopausal and receiving aromatase inhibitor therapy.

      Examples include anastrozole, letrozole, and exemestane.

    • Premenopausal pathway: Patient is premenopausal and receiving estrogen deprivation therapy.

      Examples include leuprolide acetate, Lupron Depot, Trelstar, Zoladex, anastrozole, letrozole, and exemestane.

    Treatment of bone loss in prostate cancer receiving androgen deprivation therapy

    Covered for 1 year when the patient meets the stated criterion.

    Prostate cancer bone loss: Patient is receiving androgen deprivation therapy for treatment of bone loss associated with prostate cancer.60 mg subcutaneously once every 6 months.

    Examples include Camcevi/Camcevi ETM, Lupron Depot, Eligard, Firmagon, Trelstar, Zoladex, and Orgovyx.

    Increase bone mineral density in breast cancer

    Covered for 1 year when the patient meets ONE of the following alternatives.

    Breast cancer bone mineral density pathway

    • Postmenopausal and aromatase inhibitor pathway: Patient is postmenopausal and receiving aromatase inhibitor therapy.

      Examples include anastrozole, letrozole, or exemestane.

    • Premenopausal and estrogen deprivation pathway: Patient is premenopausal and receiving estrogen deprivation therapy.

      Examples include leuprolide acetate, Lupron Depot, Trelstar, Zoladex, anastrozole, letrozole, and exemestane.

    Xgeva and its biosimilars are excluded from this policy. This policy applies to Prolia and specified Prolia biosimilars, not denosumab products marketed as Xgeva.

    Ospomyv is not covered under the pharmacy or medical benefit for Employer Plans and Individual and Family Plans. The member’s benefit plan document determines which products are covered.

    Concurrent use with another denosumab product is not covered. Patients receiving Prolia or a Prolia biosimilar should not receive another denosumab product, including Xgeva or its biosimilars, at the same time.

    For osteoporosis-related indications, denosumab must not be used as combination therapy with other osteoporosis medications. Examples include teriparatide products, Tymlos, oral or intravenous bisphosphonates, calcitonin nasal spray, and Evenity. Calcium and/or vitamin D supplements may be used with denosumab.

    Osteoporosis prevention is not a covered indication. Denosumab products are covered only for supported treatment indications described in the policy.

    Giant cell tumor of bone is not covered under this policy. The dosing used for this indication is associated with Xgeva and its biosimilars, which are outside the scope of this Prolia policy.

    Any use outside the policy’s listed supported indications is considered not medically necessary, including uses not supported by the applicable clinical and dosing criteria.

    Billing and Coding

    Covered HCPCS CodesHCPCSCovered
    C9399Unclassified drugs or biologicals
    J0897Injection, denosumab, 1 mg
    J3490Unclassified drugs
    J3590Unclassified biologics
    Q5136Injection, denosumab-bbdz (Jubbonti/Wyost), biosimilar, 1 mg
    Q5157Injection, denosumab-bmwo (Stoboclo/Osenvelt), biosimilar, 1 mg
    Q5158Injection, denosumab-bnht (Bomyntra/Conexxence), biosimilar, 1 mg
    Covered HCPCS CodesHCPCSCovered
    Q5159Injection, denosumab-dssb (Ospomyv/Xbryk), biosimilar, 1 mg
    Q5161Injection, denosumab-kyqq (aukelso/bosaya), biosimilar, 1 mg
    Q5162Injection, denosumab-nxxp (bildyos/bilprevda), biosimilar, 1 mg
    Q5166Injection, denosumab-desu (osvyrti/jubereq), biosimilar, 1 mg
    Q5167Injection, denosumab-qbde (enoby/xtrenbo), biosimilar, 1 mg
    HCPCS Code Added in Revision DetailsHCPCS
    J5166HCPCS code added in the revision details; description not provided in this window
    Severe renal impairment
    Creatinine clearance threshold< 35 mL/minute
    Applies toSevere renal impairment or chronic kidney disease pathways
    Related requirementPatients must be evaluated for chronic kidney disease mineral and bone disorder before denosumab treatment when applicable
    Oral bisphosphonate inadequate efficacy
    Trial duration12 months
    TherapyAt least one oral bisphosphonate product or oral bisphosphonate-containing product

    Provider Actions and Coverage Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of denosumab products, including Prolia and denosumab biosimilars. Requests for doses outside the policy dosing may be reviewed case by case by a Medical Director or Pharmacist.

    • Approval is recommended only when the applicable policy criteria and dosing are met.
    • Standard dosing for the covered indications is 60 mg subcutaneously once every 6 months.
    Step Therapy

    Check Preferred Specialty Management Requirements

    Before requesting a denosumab product, review the Bone Modifiers - Denosumab Products (Prolia) Preferred Specialty Management Policy (PSM033). Preferred products must generally be used before approval of a nonpreferred product.

    • Apply any preferred-product exceptions described in PSM033 and the applicable benefit plan document.

    Policy Background

    Denosumab products, including Prolia and specified biosimilars, are RANKL inhibitors used to increase bone mass and reduce fracture risk in selected patients. Covered clinical settings include osteoporosis, glucocorticoid-induced osteoporosis, and bone loss associated with cancer treatment. Patients generally have high fracture risk, such as a history of osteoporotic fracture, multiple fracture risk factors, or failure or intolerance of other osteoporosis therapy. Calcium and vitamin D supplementation is recommended during treatment.

    Definitions and Clinical Thresholds

    High fracture risk
    History of fractureHistory of osteoporotic fracture
    Risk factorsMultiple risk factors for fracture
    Prior therapy responseFailure or intolerance to other available osteoporosis therapy
    Chronic kidney disease mineral and bone disorder
    AbbreviationCKD-MBD
    MeaningChronic kidney disease mineral and bone disorder
    Required evaluationPatients with advanced chronic kidney disease should be evaluated for CKD-MBD before denosumab treatment

    Initial Therapy Criteria

    Initial authorization

    Initial approval requires prior authorization and satisfaction of one applicable coverage criteria set.

    Initial authorization requirements

    • Prior authorization is obtained for the requested denosumab product.
    • Applicable coverage criteria set: Patient meets one applicable FDA-approved or supportive-evidence indication pathway.

    Prostate cancer bone loss

    Approve for 1 year when the patient meets the following criterion.

    Prostate cancer bone loss: Patient is receiving androgen deprivation therapy for treatment of bone loss associated with prostate cancer.

    Step Therapy Requirements

    IndicationStep requirementQualifying exceptions or alternatives
    Glucocorticoid-induced osteoporosisBefore denosumab approval, the patient may need to have tried intravenous zoledronic acid or at least one oral bisphosphonate.For an oral bisphosphonate, qualifying alternatives include inadequate efficacy after a 12-month trial or significant intolerance. Other qualifying pathways include inability to take an oral bisphosphonate, severe renal impairment or chronic kidney disease with CKD-MBD evaluation, or an osteoporotic or fragility fracture.
    Postmenopausal osteoporosisBefore denosumab approval, the patient may need to have tried intravenous ibandronate or zoledronic acid, or at least one oral bisphosphonate.For an oral bisphosphonate, qualifying alternatives include inadequate efficacy after a 12-month trial or significant intolerance. Other qualifying pathways include inability to take an oral bisphosphonate, severe renal impairment or chronic kidney disease with CKD-MBD evaluation, an osteoporotic or fragility fracture, or a very low T-score.
    Osteoporosis in menBefore denosumab approval, the patient may need to have tried intravenous zoledronic acid or at least one oral bisphosphonate.For an oral bisphosphonate, qualifying alternatives include inadequate efficacy after a 12-month trial or significant intolerance. Other qualifying pathways include inability to take an oral bisphosphonate, severe renal impairment or chronic kidney disease with CKD-MBD evaluation, or an osteoporotic or fragility fracture.
    StepRequirementException
    1Use preferred denosumab products before requesting approval of a nonpreferred denosumab product.An exception may apply under the Bone Modifiers - Denosumab Products (Prolia) Preferred Specialty Management Policy (PSM033).

    Quantity Limits and Dosing

    All covered denosumab products
    Dose60 mg
    FrequencyOnce every 6 months
    Annual quantity2 doses per 12 months
    Prolia and covered denosumab biosimilars
    Dose60 mg
    FrequencyOnce every 6 months
    AdministrationSubcutaneous injection

    Site of Care and Administration

    Billing Rule

    Administer in the office by subcutaneous injection

    Administer denosumab in the office as a subcutaneous injection.

    • Dose for all indications: 60 mg once every 6 months.
    Policy Summary
    PayerCigna
    PolicyDenosumab Products (Prolia) Prior Authorization
    Policy CodePolicy IP0331
    Change TypeModified
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with the applicable diagnosis, clinical criteria, requested dose, and frequency.
    SourceLink
    On This Page
    Coverage CriteriaBilling and CodingProvider Actions and Coverage RisksPolicy BackgroundDefinitions and Clinical ThresholdsInitial Therapy CriteriaStep Therapy RequirementsQuantity Limits and DosingSite of Care and Administration
    Inadequate efficacy examplesOngoing and significant loss of bone mineral density, lack of a bone mineral density increase, and/or an osteoporotic or fragility fracture
    Very low T-score
    Very low T-score< -3.0
    Accepted measurement statusCurrent or historical T-score
    Use in criteriaQualifies as a clinical-need pathway for postmenopausal osteoporosis; it may allow bypass of the bisphosphonate trial
    Osteoporosis diagnostic T-score
    Diagnostic threshold≤ -2.5
    Measurement sitesLumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist)
    Accepted measurement statusCurrent or historical T-score
    Low bone mass T-score
    Low bone mass rangeBetween -1.0 and -2.5
    Measurement sitesLumbar spine, femoral neck, total hip, and/or 33% (one-third) radius (wrist)
    Additional requirementFor coverage through the low-bone-mass pathway, the prescriber must document high fracture risk
    Very low T-score exception
    Exception threshold< -3.0
    Applicable pathwayPostmenopausal osteoporosis treatment
    EffectAllows bypass of the bisphosphonate trial
    Billing Rule

    Submit Covered Product and Coding Information

    Medical-necessity prior authorization applies to covered denosumab products billed under the applicable listed HCPCS codes. Submit the product, indication, covered diagnosis, requested dose, and supporting clinical documentation with the authorization request.

    • Use the most appropriate codes in effect on the submission date.
    • Claims submitted without covered diagnosis and/or procedure codes may be denied as not covered.
    Step Therapy

    Preferred Product Sequencing

    Use the preferred denosumab product sequence before requesting a nonpreferred product. The request should document that the applicable preferred-product requirements have been satisfied or that an exception under PSM033 applies.

    • Refer to PSM033 for preferred products, sequencing requirements, and exceptions.
    • Benefit-plan terms may impose additional product requirements.
    Documentation Required

    Clinical Information Supporting Criteria

    Provide clinical information that demonstrates the requested indication and satisfies all applicable criteria. Documentation should support the diagnosis, disease status, relevant risk factors, prior or concurrent therapies, treatment response or intolerance, and the requested dose and frequency.

    • For breast or prostate cancer indications, document cancer status, menopausal or sex-specific status when applicable, and current aromatase inhibitor, estrogen-deprivation, androgen-deprivation therapy, or bilateral orchiectomy.
    • For osteoporosis indications, provide current or historical T-scores, fracture or fragility-fracture history, low bone mass and high-fracture-risk documentation when applicable.
    • Document prior treatment with intravenous or oral bisphosphonates, including inadequate efficacy after the required trial duration, significant intolerance, inability to swallow or remain upright, or relevant gastrointestinal disease.
    • For severe renal impairment or chronic kidney disease, document the condition and evaluation for chronic kidney disease mineral and bone disorder to reduce denosumab-induced hypocalcemia risk.
    • Include the requested denosumab product, dose, route, frequency, and treatment duration; the policy generally specifies 60 mg subcutaneously once every 6 months.
    Denial Risk

    Authorization and Criteria-Not-Met Denials

    A request may be authorized when the applicable criteria are met and the requested dosing is within the policy. If the criteria are not met, required documentation is absent, or the request is otherwise outside the policy, coverage may be denied or referred for case-by-case clinical review.

    • Doses outside established policy dosing require clinician review.
    • Approval periods for the listed indications are generally 1 year unless otherwise noted.
    Denial Risk

    Ospomyv Exclusion for Certain Plans

    Ospomyv is not covered on the pharmacy or medical benefits for Employer Plans and Individual and Family Plans. Confirm product coverage under the customer's specific benefit plan document.

    • This plan-specific exclusion applies regardless of the clinical indication unless the applicable benefit plan document provides otherwise.
    Billing Rule

    Noncovered Diagnosis or Coding

    Reimbursement is not allowed when denosumab is billed for a diagnosis or condition that is not covered under this policy. Use covered diagnosis and procedure codes and submit the most appropriate codes effective on the date of submission.

    • Claims for services not accompanied by covered code(s) may be denied as not covered.
    • The customer's benefit plan document and applicable coverage mandates may supersede this policy.
    Step Therapy

    Preferred Product Requirement and Exceptions

    The requested product must meet the preferred-product requirements before approval. Exceptions may apply only as described in the Preferred Specialty Management Policy (PSM033) and the applicable benefit plan document.

    • Document the required use of preferred products or the basis for an applicable exception.
    Denial Risk

    Osteoporosis Prevention Not Covered

    Denosumab products are not medically necessary for osteoporosis prevention. The policy covers treatment indications that meet the stated criteria, not prevention of osteoporosis.

    • Requests solely for osteoporosis prevention may be denied.
    Denial Risk

    Concurrent Osteoporosis Medications Not Covered

    Concurrent use of denosumab products with other medications for osteoporosis is not covered for osteoporosis-related indications. Calcium and/or vitamin D supplements may be used with denosumab.

    • Examples of noncovered concurrent osteoporosis medications include teriparatide products, Tymlos, oral or intravenous bisphosphonates, calcitonin nasal spray, and Evenity.
    Denial Risk

    Concurrent Denosumab Products Not Covered

    Patients receiving Prolia or a denosumab biosimilar should not receive another denosumab product concomitantly. Concurrent administration is not covered.

    • Examples of other denosumab products include Xgeva and Xgeva biosimilars.
    Denial Risk

    Giant Cell Tumor of Bone Not Covered

    Giant cell tumor of bone is not covered under this Prolia policy. Denosumab dosing for this condition is associated with Xgeva or its biosimilars, which have a separate indication.

    • Requests for giant cell tumor of bone may be denied under the Prolia policy.
    Denial Risk

    Other Unsupported Uses

    Denosumab products for any other use not supported by the policy criteria or sufficient evidence are considered not medically necessary. This list is not all-inclusive and may be updated as new published data become available.

    • Submit documentation linking the requested product to a covered indication and all applicable criteria.
    • Unsupported, noncovered, or otherwise unlisted uses may be denied.
    Low bone mass
    T-score rangeBetween -1.0 and -2.5
    Measurement sitesLumbar spine, femoral neck, total hip, or 33% (one-third) radius
    Measurement statusCurrent or historical T-score
    Other denosumab product
    DefinitionA denosumab product other than Prolia or a Prolia biosimilar
    ExamplesXgeva or its biosimilars
    Concurrent useShould not be administered concomitantly with Prolia or a Prolia biosimilar
    60 mg subcutaneously once every 6 months.

    Examples include Camcevi, Lupron Depot, Eligard, Firmagon, Trelstar, Zoladex, and Orgovyx.

    Breast cancer bone mineral density

    Approve for 1 year when the patient meets ONE of the following pathways.

    Breast cancer bone mineral density pathway

    • Postmenopausal and aromatase inhibitor pathway: Patient is postmenopausal and receiving aromatase inhibitor therapy.

      Examples include anastrozole, letrozole, or exemestane.

    • Premenopausal and estrogen deprivation pathway: Patient is premenopausal and receiving estrogen deprivation therapy.

      Examples include leuprolide acetate, Lupron Depot, Trelstar, Zoladex, anastrozole, letrozole, and exemestane.